Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00033085 · ClinicalTrials.gov registry record · Phase 2

Ondansetron for the Treatment of Cocaine Dependence - 1

A Phase 2 study of Cocaine-Related Disorders and Drug Administration Schedule, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
Phase 2
Development phase
60
Enrollment target
1
Study location

NCT00033085 is a Phase 2 study of Cocaine-Related Disorders and Drug Administration Schedule that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 60 participants, roughly in line with the 61-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00033085, a Phase 2 study of Cocaine-Related Disorders and Drug Administration Schedule, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the efficacy and safety of ondansetron to reduce cocaine use in subjects with cocaine dependence.

Interventions

  • DRUG Ondansetron

Study Locations (1)

Texas

  • University of Texas Hlth Sci Ctr San Ant - San Antonio

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2001-05
Est. Completion 2002-12
Phase Phase 2

What the Registry Record Tells You About NCT00033085

The ClinicalTrials.gov registry entry for NCT00033085 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 61-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cocaine-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Ondansetron is the first listed.

NCT00033085 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00033085 about?

NCT00033085 is a clinical study titled "Ondansetron for the Treatment of Cocaine Dependence - 1". The purpose of this study is to assess the efficacy and safety of ondansetron to reduce cocaine use in subjects with cocaine dependence.

What is the current status of trial NCT00033085?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2001-05. Estimated completion is 2002-12.

What conditions does trial NCT00033085 study?

This clinical trial studies the following conditions: Cocaine-Related Disorders, Drug Administration Schedule.

What interventions are being tested in trial NCT00033085?

The interventions under investigation include: Ondansetron (DRUG).

Who is sponsoring clinical trial NCT00033085?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00033085 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cocaine-Related Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.